Some of functionality may not work while you disabled JavaScript. Enable JavaScript for better User Exprience.
Access here alternative investment news about Velicept Therapeutics Raises An Additional $15M In Series B Round, Initiates Phase 2b Study Evaluating Once Daily Dosing Of Solabegron In Patients With Overactive Bladder (oab) And Receives Issuance Of Additional U.s. Patent
Venture Capital

Velicept Therapeutics Raises An Additional $15M In Series B Round, Initiates Phase 2b Study Evaluating Once Daily Dosing Of Solabegron In Patients With Overactive Bladder (oab) And Receives Issuance Of Additional U.s. Patent

by vcaonline.com posted 11months ago 264 views
Velicept Therapeutics Raises an Additional $15 Million in Series B Round, Initiates Phase 2b Study Evaluating Once Daily Dosing of Solabegron in Patients with Overactive Bladder (OAB) and Receives Issuance of Additional U.S. Patent -Additional Funding to Advance Phase 2b Development Program in OAB- -Enrollment for Second Phase 2 Study Well Underway- -Issuance of U.S. Patent No.

In this article